An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss when given ...

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...

Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...

Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...

Amgen's study of the drug Maritide in people with Type 2 diabetes showed noteworthy reductions in HbA1c and weight. The ...

The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite.

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

Both stocks are strong options for dividend seekers to add to their portfolios. Let's examine closely how 2026 could unfold ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...

From the King Kong of weight-loss jabs to the Godzilla of the category, the GLP-1 industry is undergoing big changes ...